Inactive Instrument

News Alseres Pharmaceuticals, Inc. Other OTC

Equities

Alseres Pharmaceuticals, Inc. cancelled the acquisition of E-IACFT Injection from Navidea Biopharmaceuticals, Inc.	15-04-21	CI
Alseres Pharmaceuticals, Inc. will Change its Ticker to ALSE from ALSED	15-01-29	CI
Alseres Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt	14-04-10	CI
Alseres Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt	13-04-01	CI
Alseres Pharmaceuticals, Inc. Licenses Altropane Rights to Navidea Biopharmaceuticals	12-08-06	CI
Alseres Pharmaceuticals, Inc. entered into an agreement to acquire E-IACFT Injection from Navidea Biopharmaceuticals, Inc for $3.4 million.	12-08-06	CI
Alseres Pharmaceuticals, Inc. Taken Out Licensing Agreement with Alseres Pharmaceuticals, Inc	12-08-02	CI
Alseres Pharmaceuticals, Inc. Reports License of Altropane(R) Worldwide Rights to Navidea Biopharmaceuticals, Inc	12-07-31	CI
Alseres Pharmaceuticals, Inc. announced that it has received $34.4 million in funding from Highbridge Capital Management, LLC, Ingalls & Snyder LLC, and other investors.	12-07-17	CI
Navidea Biopharmaceuticals to Continue its Diligence Through the End of July 2012 with Alseres Pharmaceuticals, Inc. to License E-IAFCT Injection	12-07-02	CI
Alseres Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt	12-03-29	CI
Navidea Biopharmaceuticals, Inc. Signs Option Agreement with Alseres Pharmaceuticals, Inc., to License Altropane	12-01-26	CI

No results for this search